9 completed, 6 terminated. 11 Phase 2, 2 Phase 1, 1 Early Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 7, Terminated 4 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Early Phase 1 | 1 | Completed 1 |
| Not applicable | 1 | Terminated 1 |
Follow Stage IIIA Melanoma: new trials by email Literature Review of Stage IIIA Melanoma trials Research Report on Stage IIIA Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery siRNA-transfected peripheral blood mononuclear cells APN401, laboratory biomarker analysis - Recurrent Melanoma, Recurrent Pancreatic Cancer | Phase 1 | Completed | Wake Forest University Health Sciences | 17 | 2014-12-01 | 2018-07-03 |
| High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery aldesleukin, ipilimumab, laboratory biomarker analysis - Recurrent Melanoma, Stage IIIA Melanoma | Phase 2 | Terminated | CINJRegulatory | 9 | 2014-11-26 | 2023-07-18 |
| Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic cytology specimen collection procedure, MEK 162 therapy or molecularly targeted therapy, therapeutic procedure - Recurrent Melanoma, Stage IIIA Melanoma | Phase 2 | Completed | Yale University | 49 | 2014-05-01 | 2020-01-02 |
| Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery cabozantinib-s-malate, vemurafenib, laboratory biomarker analysis - Recurrent Melanoma, Stage IIIA Melanoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 5 | 2013-05-01 | 2014-09-25 |
| Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery dabrafenib, trametinib, laboratory biomarker analysis - Recurrent Melanoma, Stage IIB Melanoma (Locally Advanced) | Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 13 | 2013-01-01 | 2017-06-23 |
| Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery Montanide ISA 51 VG, MART-1 antigen, laboratory biomarker analysis - Recurrent Melanoma, Stage IIA Melanoma | Early Phase 1 | Completed | Mayo Clinic | 30 | 2012-10-01 | 2018-10-09 |
| FDG-PET in Advanced Melanoma [18F]fluorodeoxyglucose, Molecular assays on biopsied tissue, positron emission tomography - Recurrent Melanoma, Stage IIIA Melanoma | Not applicable | Terminated | Vanderbilt-Ingram Cancer Center | 3 | 2012-05-01 | 2017-04-13 |
| Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib Akt inhibitor MK2206, selumetinib, laboratory biomarker analysis - Recurrent Melanoma, Stage IIIA Melanoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2012-01-01 | 2014-06-18 |
| Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery axitinib, laboratory biomarker analysis - Extraocular Extension Melanoma, Metastatic Intraocular Melanoma | Phase 2 | Terminated | Roswell Park Cancer Institute | 25 | 2012-01-01 | 2018-05-09 |
| Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma therapeutic conventional surgery, laboratory biomarker analysis, Axitinib - Melanoma, Malignant Melanoma | Phase 2 | Completed | University of California, Irvine | 11 | 2011-12-01 | 2021-01-20 |
| Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery imatinib mesylate, laboratory biomarker analysis - Acral Lentiginous Malignant Melanoma, Recurrent Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 30 | 2007-04-01 | 2014-12-23 |
| Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma dasatinib - Recurrent Melanoma, Stage IIIA Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 39 | 2006-12-01 | 2014-05-15 |
| Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma tyrosinase peptide, gp100 antigen, MART-1 antigen - Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 40 | 2004-06-01 | 2015-04-15 |
| Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma gp100 antigen, tyrosinase peptide, recombinant MAGE-3.1 antigen - Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size | Phase 2 | Completed | University of Southern California | 42 | 2004-05-01 | 2014-05-22 |
| Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma HPV 16 E7:12-20, gp100:209-217(210M), laboratory biomarker analysis - Recurrent Melanoma, Stage IA Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 36 | 1999-04-01 | 2017-02-20 |
Melanoma (15) · Uveal Melanoma (3) · Carcinoma, Renal Cell (1) · Pancreatic Neoplasms (1)
Neoplasms (15) · Neoplasms by Histologic Type (15) · Neoplasms by Site (15) · Neoplasms, Germ Cell and Embryonal (15) · Neoplasms, Nerve Tissue (15) · Neuroectodermal Tumors (15) · Neuroendocrine Tumors (15) · Nevi and Melanomas (15) · Skin Diseases (15) · Skin Neoplasms (15) · Skin and Connective Tissue Diseases (15) · Eye Diseases (3) · Eye Neoplasms (3) · Uveal Diseases (3) · Uveal Neoplasms (3)
montanide ISA 51 (3) · Axitinib (2) · MART-1 Antigen (2) · incomplete Freund's adjuvant (2) · AZD 6244 (1) · CTLA-4 Antigen (1) · Coal Tar (1) · Dasatinib (1) · Gene Expression (1) · Imatinib Mesylate (1) · Immunohistochemistry (1) · Interleukin-2 (1) · Ipilimumab (1) · MAGEA3 protein, human (1) · MK 2206 (1)
National Cancer Institute (NCI) (6) · Vanderbilt-Ingram Cancer Center (2) · CINJRegulatory (1) · Mayo Clinic (1) · Roswell Park Cancer Institute (1) · University of California, Irvine (1) · University of Southern California (1) · Wake Forest University Health Sciences (1) · Yale University (1)
United States (15)
Jeffrey Weber (2) · Harriet Kluger (1) · Howard Kaufman (1) · Jason Luke (1) · Jeffrey Sosman (1) · John P. Fruehauf, MD, PhD (1) · Mark Kelley (1) · Matuesz Opyrchal, MD (1) · Patricia LoRusso, D.O. (1) · Pierre Triozzi (1) · Richard Carvajal (1) · Svetomir Markovic, M.D., Ph.D. (1) · Tom Yankeelov, PhD (1) · Walter J. Urba, MD, PhD (1)
PMID 21642685, PMID 25797743, PMID 31998643
N01CM00100 (1), N01CM62204 (1), N01CM62206 (1), P30CA006516 (1), P30CA008748 (1), P30CA012197 (1), P30CA016056 (1), P30CA016359 (1), P30CA022453 (1), P30CA068485 (1), P30CA072720 (1), R21CA082614 (1), U01CA062490 (1), UM1CA186709 (1)